Olanzapine in the treatment of schizophrenia in adolescents – mechanisms of action and therapeutic efficacy

Abstract

The aim of the study is to review mechanisms, efficacy, safety, pharmacokinetics, and guideline positions of olanzapine in youth, with comparison to adults. The authors present a narrative synthesis of randomized trials, open-label studies, meta-analyses, and major guidelines (APA, NICE, Canadian), with focused appraisal of pediatric data. Results show that olanzapine’s multi-receptor antagonism (D₂, 5-HT₂A/2C, H₁, muscarinic, α₁) underpins robust antipsychotic effects. In adolescents, short-term RCTs show significant improvement in PANSS/BPRS-C and YMRS versus placebo; efficacy is broadly comparable to risperidone and aripiprazole. Pharmacokinetics are similar to adults, though exposure is ~27–34% higher in youth. Adverse effects ‒ especially weight gain, dyslipidemia, hyperprolactinemia, and glycemic abnormalities ‒ are more pronounced in adolescents. Guidelines endorse olanzapine as an option for schizophrenia and as first-line for acute mania; OFC is recommended for bipolar depression by most but not NICE. LAI olanzapine is not approved <18 years. Olanzapine is effective in adolescent psychosis and mania but carries substantial metabolic liability. Given no clear efficacy advantage over other SGAs, it is best positioned as a second-line agent in youth, with preference for monotherapy, cautious dosing, and stringent metabolic monitoring. Evidence for benefits on negative and cognitive symptoms in adolescents remains limited.